Bristol Videx Once-Daily Dosing Restricted After Unfavorable Trial Results
Executive Summary
Labeling for Bristol-Myers Squibb's Videx (didanosine) has been revised to recommend against once-daily dosing for most patients following negative findings from a clinical trial using the new 200 mg formulation of the drug.